Related to Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy

• RuiYi, CMC Collaborate to Speed mAb Development
  
• Medarex Taps Lonza for Biomanufacturing
  
• Lonza to Produce Anti-RhD Antibodies for LFB’s Phase III Trials
  
• Alnara Selects Lonza for Commercial Manufacture of Pancreatic Insufficiency Therapy
  
• Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody
  
• Cellectis to Apply Its Meganuclease Technology to Engineer Lonza Cell Line
  
• Lonza to Manufacture HGS and GSK’s Lupus Drug Benlysta
  
• Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line
  
• Lonza Acquires Vivante to Expand into Viral-Based GMP Manufacturing
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• Dalton and Lonza Ink Contract Chemistry and Manufacturing Agreement
  
• Kalobios Chooses BioWa and Lonza’s Potelligent CHOK1SV Cell Line
  
• Genesis Signs On Lonza as Production Partner for Cancer Cell Therapy
  
• Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate
  
• Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
  
• Lonza to Manufacture Heart Failure Enzyme Replacement Therapy
  
• Lonza to Provide Cell-Line and Process-Development Services for Athera’s mAb
  
• Enobia Raises $40M to Further Develop Phase II-Stage ERT for Hypophosphatasia
  
• Agennix Contracts Lonza for Commercial Manufacturing of Its Oral NSCLC Immunotherapy
  
• Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate